Results 131 to 140 of about 13,813 (161)

Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic <i>HER2</i>-Mutant Non-Small Cell Lung Cancer. [PDF]

JCO Precis Oncol
Lovly CM, Baik C, Nagasaka M, Patil T, Maruti SS, Stanhope S, Kaya NA, Herbertz S, Nordstrom B, Evans K, Le X.   +10 more
europepmc   +1 more source

Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First-Line Treatment of HER2+ MBC: A Multicenter Real-World Study. [PDF]

Cancer Med
Kuang M, Li J, Bian L, Zhang S, Wang T, Tong Z, Ouyang Q, Jiang Z.   +7 more
europepmc   +1 more source

Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2-positive metastatic colorectal cancer. [PDF]

J Comp Eff Res
Watkins C, Simon C, Martin P, Leadley R, Redhead G, Neuberger E, Bartley K.   +6 more
europepmc   +1 more source

The applicability of the 21-gene assay to inform chemotherapy benefit in lymph node positive hormone receptor positive male breast cancer. [PDF]

Breast Cancer Res Treat
Gaba AG, Cao L, Renfrew RJ.
europepmc   +1 more source

First- Versus Second- or Subsequent-Line Use of Cyclin-Dependent Kinase 4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic or Recurrent Breast Cancer: A Multicenter, Retrospective Cohort Study. [PDF]

Medicina (Kaunas)
Yao S, Imoto S, Tsuchiya A, Isaka H, Seki H, Asaga S, Yokoi S, Koneri K, Maeda H, Goi T.   +9 more
europepmc   +1 more source

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. [PDF]

Cancer Discov
Siegel F, Siegel S, Kotýnková K, Karsli Uzunbas G, Korr D, Tomono H, Andersen S, Denney D, Berger M, Schulze VK, Lewis TA, Kaplan B, Golfier S, Mortier J, Hillig RC, Boemer U, Petersen K, Eis K, Williams S, Rüttinger D, Cherniack AD, Loong HH, Goto K, Grassi P, Meyerson M, Greulich H.   +25 more
europepmc   +1 more source

Molecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status. [PDF]

Chin Med J (Engl)
Yang X, Wang J, An H, He Y, Gan Y, Chen Q, Liu B, Tang W, Fu G, Jiang Z.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition

Gastroenterology, 2017
Drugs that inhibit the erb-b2 receptor tyrosine kinase 2 (ERBB2 or HER2) are the standard treatment of patients with different types of cancer, including HER2-overexpressing gastroesophageal tumors. Unfortunately, cancer cells become resistant to these drugs, so overall these drugs provide little benefit to patients with these tumors.
Eva A Ebbing, Anne Steins, Evelyn Fessler   +2 more
exaly   +3 more sources

Inhibition of Erb-B2 Receptor Tyrosine Kinase 3 and Associated Regulatory Pathways Potently Impairs Malignant Peripheral Nerve Sheath Tumor Proliferation and Survival

The American Journal of Pathology, 2023
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, currently untreatable Schwann cell-derived neoplasms with hyperactive mitogen-activated protein kinase and mammalian target of rapamycin signaling pathways. To identify potential therapeutic targets, previous studies used genome-scale shRNA screens that implicated the neuregulin-1 ...
Laurel E. Black, Jody F. Longo, Joshua C. Anderson, Steven L. Carroll   +3 more
openaire   +2 more sources

Erb-B2 receptor tyrosine kinase 2 knockdown inhibits retinoblastoma progression via Wnt/β-catenin signaling pathway in vitro

JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2021
B, Liu, T, Gao, H Y, Wu, M, Wan
openaire   +2 more sources